Why the study?
It is essential for the medical profession to critically evaluate evidence related to detection and management of hypertrophic cardiomyopathy.
This document serves as the 2011 ACCF/AHA executive summary for the clinical diagnosis and management of hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Recognize end-stage HCM progression in practice; reinforces guideline inclusion of adverse remodeling phenotypes.
essential that the medical profession play a central role in critically evaluating the evidence related to drugs, devices, and procedures for the detection, management, or Clinical Guideline * Characterized by systolic dysfunction (EF 50%), often associated with LV remodeling, including cavity enlargement and wall thinning, and because of diffuse myocardial scarring.
No takes yet. Share an insight, caveat, or question.
Gersh et al. (2011) studied this question. Hypertrophic cardiomyopathy can feature systolic dysfunction (EF 50%) associated with left ventricular remodeling, cavity enlargement, wall thinning, and diffuse myocardial scarring.
Synapse has enriched 10 related papers. Consider them for comparative context: